Antioxidants and cancer
This article was originally published in The Tan Sheet
Executive Summary
CFSAN postpones making a decision on the antioxidant vitamin/cancer health claim until Feb. 23. The agency already had postponed its decision to Nov. 30 and again to Dec. 22, stating the numerous types of cancers and antioxidants involved make reviewing the claim more time-consuming. CFSAN also notes in its Dec. 22 letter to Washington, D.C.-based Emord & Associates that it is reviewing the vitamin E/heart disease health claim as well as the law firm's Dec. 12 letter asserting the qualified B vitamin claim should recognize homocysteine as a vascular disease risk factor